---
title: "MEDICUS PHARMA LTD C/WTS 15/11/2029(TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -0.42"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/239913528.md"
datetime: "2025-05-12T21:23:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/239913528.md)
  - [en](https://longbridge.com/en/news/239913528.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/239913528.md)
generator: "portal-rs"
---

# MEDICUS PHARMA LTD C/WTS 15/11/2029(TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -0.42

EPS: As of FY2025 Q1, the actual value is USD -0.42.

### Segment Revenue

-   **General and Administrative Expenses**: $3,120,060 for the three months ended March 31, 2025, compared to $1,385,981 for the same period in 2024, representing an increase of $1,734,079.
-   **Research and Development Expenses**: $2,006,214 for the three months ended March 31, 2025, compared to $321,377 for the same period in 2024, representing an increase of $1,684,837.

### Operational Metrics

-   **Net Loss**: $5,102,408 for the three months ended March 31, 2025, compared to $1,707,358 for the same period in 2024.
-   **Loss from Operations**: $5,126,274 for the three months ended March 31, 2025, compared to $1,707,358 for the same period in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: $3,940,994 for the three months ended March 31, 2025, compared to $1,176,933 for the same period in 2024.
-   **Net Cash Provided by Financing Activities**: $3,759,101 for the three months ended March 31, 2025, compared to $0 for the same period in 2024.

### Unique Metrics

-   **Accumulated Deficit**: $34,006,311 as of March 31, 2025.

### Future Outlook and Strategy

-   **Core Business Focus**: The company expects to continue incurring significant operating losses and may never become profitable. It plans to finance operations through equity sales and non-dilutive funding sources.
-   **Non-Core Business**: The company has entered into a Standby Equity Purchase Agreement with Yorkville, allowing it to sell up to $15,000,000 of common shares over 36 months.

### Related Stocks

- [MDCXW.US](https://longbridge.com/en/quote/MDCXW.US.md)

## Related News & Research

- [Why CF Industries (CF) Is Up 6.0% After Blue Ammonia JV and Leadership Transition News](https://longbridge.com/en/news/298114954.md)
- [Best Buy’s Net Interest Income Sensitive to Rate Moves Despite Strong Cash Position](https://longbridge.com/en/news/298124585.md)
- [Is Camtek (CAMT) Options Frenzy Quietly Reframing Its Near‑Term Earnings Story?](https://longbridge.com/en/news/298114664.md)
- [Elon Can’t Build His Empire Alone](https://longbridge.com/en/news/298114289.md)
- [The Bull Case For Natera (NTRA) Could Change Following New Signatera Lymphoma Data And Komen Partnership](https://longbridge.com/en/news/298111249.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**